82/100 · Critical
Manufactured by Amneal Pharmaceuticals LLC
High Safety Concerns with Carbidopa and Levodopa: Falls and Neurological Issues Predominate
97,592 FDA adverse event reports analyzed
Last updated: 2026-05-12
CARBIDOPA AND LEVODOPA is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Amneal Pharmaceuticals LLC. Based on analysis of 97,592 FDA adverse event reports, CARBIDOPA AND LEVODOPA has a safety score of 82 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for CARBIDOPA AND LEVODOPA include FALL, DRUG INEFFECTIVE, HALLUCINATION, TREMOR, DYSKINESIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CARBIDOPA AND LEVODOPA.
Carbidopa And Levodopa has a safety concern score of 82 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 97,592 adverse event reports for this medication, which is primarily manufactured by Amneal Pharmaceuticals Llc.
The most commonly reported adverse events include Fall, Drug Ineffective, Hallucination. Of classified reports, 54.9% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Falls are the most common serious adverse event, indicating a significant risk of injury.
Neurological symptoms such as hallucinations, dyskinesia, and confusion are frequent and serious. Death reports are notable, suggesting a high risk of severe adverse outcomes. Drug ineffectiveness and on-off phenomenon are common, indicating variability in therapeutic response. Interactions and misuse are frequent, highlighting the need for careful management.
Patients taking Carbidopa And Levodopa should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Carbidopa and Levodopa can interact with other medications, and misuse can lead to serious adverse events. Patients should be closely monitored for interactions and side effects. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Carbidopa And Levodopa received a safety concern score of 82/100 (high concern). This is based on a 54.9% serious event ratio across 45,752 classified reports. The score accounts for 97,592 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Male: 24,294, Female: 18,699, Unknown: 36. The most frequently reported age groups are age 76 (1,171 reports), age 77 (1,171 reports), age 73 (1,160 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 45,752 classified reports for CARBIDOPA AND LEVODOPA:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Carbidopa and Levodopa can interact with other medications, and misuse can lead to serious adverse events. Patients should be closely monitored for interactions and side effects.
If you are taking Carbidopa And Levodopa, here are important things to know. The most commonly reported side effects include fall, drug ineffective, hallucination, tremor, dyskinesia. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should report any unusual symptoms to their healthcare provider immediately. Follow prescribed dosing instructions and do not alter the regimen without medical advice. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
Regulators continue to monitor the safety profile of Carbidopa and Levodopa, with ongoing efforts to improve patient safety and management practices.
The FDA has received approximately 97,592 adverse event reports associated with Carbidopa And Levodopa. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Carbidopa And Levodopa include Fall, Drug Ineffective, Hallucination, Tremor, Dyskinesia. By volume, the top reported reactions are: Fall (4,293 reports), Drug Ineffective (3,953 reports), Hallucination (3,734 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Carbidopa And Levodopa.
Out of 45,752 classified reports, 25,127 (54.9%) were classified as serious and 20,625 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Carbidopa And Levodopa break down by patient sex as follows: Male: 24,294, Female: 18,699, Unknown: 36. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Carbidopa And Levodopa adverse events are: age 76: 1,171 reports, age 77: 1,171 reports, age 73: 1,160 reports, age 75: 1,134 reports, age 78: 1,131 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Carbidopa And Levodopa adverse event reports is Amneal Pharmaceuticals Llc. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Carbidopa And Levodopa include: Death, Parkinson^S Disease, Dizziness, Nausea, Confusional State. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Carbidopa And Levodopa to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Carbidopa And Levodopa has a safety concern score of 82 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Falls are the most common serious adverse event, indicating a significant risk of injury.
Key safety signals identified in Carbidopa And Levodopa's adverse event data include: Falls (4293 reports). Death (2728 reports). Hallucinations (3734 reports). Dyskinesia (2902 reports). Drug ineffectiveness (3953 reports). These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Carbidopa and Levodopa can interact with other medications, and misuse can lead to serious adverse events. Patients should be closely monitored for interactions and side effects. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Carbidopa And Levodopa.
Patients should report any unusual symptoms to their healthcare provider immediately. Follow prescribed dosing instructions and do not alter the regimen without medical advice.
Carbidopa And Levodopa has 97,592 adverse event reports on file with the FDA. Neurological symptoms such as hallucinations, dyskinesia, and confusion are frequent and serious. The volume of reports for Carbidopa And Levodopa reflects both the drug's usage level and the vigilance of the reporting community.
Regulators continue to monitor the safety profile of Carbidopa and Levodopa, with ongoing efforts to improve patient safety and management practices. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Amneal Pharmaceuticals LLC and compare their safety profiles:
The following drugs share commonly reported adverse reactions with CARBIDOPA AND LEVODOPA:
Drugs related to CARBIDOPA AND LEVODOPA based on therapeutic use, drug class, or shared indications: